Abstract Number: 151

The rapid onset of multiple squamous cell carcinomas in two patients commenced on Ustekinumab as treatment of psoriasis

L.C. Young, D. Czarnecki

Meeting: 2012 Dermcoll

Session Information

Date: -

Session Title: Poster Presentations

Session Time: -

We report the cases of two patients who developed multiple
cutaneous squamous cell carcinomas (SCCs) after commencement
of ustekinumab, as treatment of moderate to
severe plaque type psoriasis. Ustekinumab represents a
human monoclonal antibody with a novel mechanism,
selectively targeting the shared p40 subunit of interleukin-
12 (IL-12) and interleukin-23 (IL-23). Its effi cacy has
been well documented in three large phase III trials
(PHOENIX I, PHEONIX 2, ACCEPT1). Safety data on this
newer biological agent continues to grow. To date, no link
between ustekinumab and cutaneous carcinogenesis has
been demonstrated; and to our knowledge, this series is the
fi rst of its kind. Importantly, both these patients had multiple
independent risk factors for developing non-melanoma
skin cancers (NMSC); however the specifi c time
correlation with the administration of ustekinumab is of
note. Our report suggests that ustekinumab may promote
cutaneous carcinogenesis in predisposed individuals.